#147: Phase Ib open-label study to evaluate safety, tolerability, immunogenicity and efficacy of multiple subcutaneous injections of PolyPEPI1018 vaccine as an add-on immunotherapy to TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC) (OBERTO-201)

Authors: Joleen M Hubbard¹, Tyler Zemla¹, Rondell P Graham¹, Zhaohui Jin¹, Mojun Zhu¹, Jessica L. Mitchell¹, Eva Vegh², Orsolya Lőrincz³, Zsolt Csiszovszki³, Mariann Kremlitzka³, Eszter Somogyi³, Levente Molnár³, József Tóth³, Enikő R Tőke³ ¹Mayo Clinic, Rochester, MN; ²South Pest Center Hospital, St. Laszlo Hospital, Oncology, Budapest, Hungary; ³Treos Bio Zrt., Viola utca 2., Veszprém 8200, Hungary


Background / Rationale

- Regorafenib and trifluridine/tipiracil (TAS-102) are treatment options for refractory mCRC as third-line therapy, with similar efficacy
- TAS-102 has statistically less toxicity of any grade compared with Regorafenib¹
- MSS mCRC subjects do not benefit from checkpoint inhibitor immunotherapy; TAS-102 in combination with Nivolumab resulted in no improvement of PFS²
- PolyPEPI1018 is an off-the-shelf, multi-peptide vaccine containing 6 immunogenic peptides (30mers) derived from 7 tumor associated antigens frequently expressed in patients with CRC, administered with Montanide ISA51 VG adjuvant
- PolyPEPI1018 successfully induced anticancer immunity and triggered recruitment and infiltration of cytotoxic T cells into the tumor of MSS mCRC subjects demonstrating also early evidence of clinical activity, in first-line mCRC³
- Here we report the initial results of the phase Ib study of PolyPEPI1018 vaccine plus TAS-102 in late-stage MSS mCRC patients.

Methods:


Patients with MSS mCRC who have progressed on ≤2 lines of prior chemotherapy regimen for mCRC received PolyPEPI1018 subcutaneously on days 1 and 15 and TAS-102 orally twice daily on days 1-5 and 8-15 of a 28-day cycle. Treatment continued for up to 7 cycles until disease progression or unacceptable toxicity. Blood and biopsies were collected for immunological assessments.

Study design




Key eligibility criteria:	Outcome measures:
 Metastatic CRC that is MSS (non-MSI-H) Willing to undergo pre/post biopsies 2 prior lines of therapy for advanced/mCRC Measurable disease 	 Primary endpoint: Safety Secondary endpoints: PFS, ORR (per RECIST 1.1), OS
ECOG PS 0-1No Active Brain Mets	 Immune-related markers Change in TILs in pre/post biopsies Clinical-marker correlations with HLA

Patient Characteristics (N=15)				
RAS Status		Primary Cancer Site		
KRAS Mutant	11 (73.3%)	Colon, sigmoid	6 (40.0%)	
NRAS Mutant	1 (6.7%)	Rectum	5 (33.3%)	
Wildtype	2 (13.3%)	Other	2 (13.3%)	
Unknown	1 (6.7%)	Prior Treatment Regimens		
BRAF Status		1	1 (6.7%)	
Wildtype	14 (93.3%)	2	14 (93.3%)	
Unknown	1 (6.7%)	Liver Met.		
		N	4 (26.7%)	
		Υ	11 (73.3%)	



Main conclusions

- PolyPEPI1018 in combination with TAS-102 is a novel regimen with clinical activity in non-liver MSS mCRC:
- Robust immunological responses induced by multiple vaccine peptides for patients with longer PFS • Recruitment and infiltration of CD8+ T cells into the tumor
- PolyPEPI1018 activity in combination with TAS-102 is consistent with previous clinical data obtained for combination with other chemotherapies³
- mPFS = 7.6 months (95% CI 4.4 NE)
- OS = not fully mature (median follow up = 7.7 (95% CI 5.6 NE) months)
- DCR = 53% (patients with no-liver met controlled their tumor growth)
- Safety profile was similar to TAS-102 alone⁴
- Frequent dosing of PolyPEPI1018 to multiple injection sites was well-tolerated
- Limited to no clinical activity was noted in patients with liver metastatic disease




Results


No SAEs leading to treatment interruption were noted; Frequent dosing of PolyPEPI1018 did not significantly increase the frequency of local reactions

Treatment	Local reactions (max Grade)				
	Gr 0	Gr 1	Gr 2	Gr 3	Gr 4
Cycle 1	7 (46.7%)	7 (46.7%)	1 (6.7%)	0 (0.0%)	0 (0.0%)
All cycles	1 (6.7%)	9 (60.0%)	5 (33.3%)	0 (0.0%)	0 (0.0%)

Adverse Events (at least possibly related to treatment)	Grade				
	2		3		
	N	%	N	%	
Fatigue	5	33.3	3	20.	
Neutrophil count decreased	4	26.7	3	20.	
White blood cell decreased	5	33.3	1	6.	
Anemia	5	33.3			
Lymphocyte count decreased	1	6.7	3	20.	
Nausea	3	20.0	1	6.	
Diarrhea			2	13.	
Dysgeusia	2	13.3			
Anorexia	1	6.7			
Chills	1	6.7			
Dyspnea	1	6.7			
Fever	1	6.7			
Myalgia			1	6.	
Rash maculo-papular			1	6.	



Tumor responses: DCR = 53 %



- Increased density of CD8+ T cells post-treatment for patient with longer PFS
- No infiltration of Tregs after treatment

References

¹Sonbol MB. Oncologist (2019) 24 (9) ²Patel MR. Cancer Med (2021) 10 (4)

Acknowledgement

We wish to thank the patients and their families, the investigators and the site staff members. Oberto-201 is an investigator initiated trial. This work was funded by the US Army Medical Research and Material Command, grant #W81XWH2010810.





• Post-treatment recruitment of TILs into core tumor or stroma for 2/3 subjects as detected by Immunoscore CR TL[®]

³Hubbard JM. CCR (2022) 28 (13) ⁴Mayer RJ. NEJM (2015) 20 (372)



.Contact: Please send your correspondence to: <u>Hubbard.Joleen@mayo.edu</u> or <u>Eniko.Toke@treosbio.com</u> Copies of this poster obtained through Quick Response (QR) code are for personal use only and may not be reproduced without permission of ASCO(R) and the Author of this poster